Objective. To evaluate the efficacy of neuroprotective therapy in carotid ischemic stroke. Material and methods. An open comparative study of combined neuroprotective therapy in comparison with standard treatment has been carried out in 25 patients with carotid ischemic stroke of moderate severity in the acute period of disease. Patients received cytoflavin, gliatilin and actovegin, along with basic therapy, during 15 days. Patient's state was assessed every 5 days using the NIHSS. The Barthel index was estimated in the 21st day. Results and conclusion. By the end of treatment, the degree of neurological deficit was significantly lower in patients treated with the combination of the neuroprotectors. The better functional rehabilitation to the 21st day and the positive dynamics of inflammation indices and free-radical processes were shown in patients of the main group.
Functional autonomic disorders occupy a significant part in the practice of neurologists and professionals of other specialties as well. However, there is no generally accepted classification of such disorders. In this paper the authors tried to show that functional autonomic pathology corresponds to the concept of somatoform disorders combining syndromes manifested by visceral, borderline psychopathological, neurological symptoms that do not have an organic basis. The relevance of the problem of somatoform disorders is that on the one hand many health professionals are not familiar enough with manifestations of borderline neuropsychiatric disorders, often forming functional autonomic disorders, and on the other hand they overestimate somatoform symptoms that are similar to somatic diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.